Prohost Biotech - Exclusive Biotech Research - A Comprehensive Resource for Biotech News

Prohost Letter #439

February 19, 2020 0

Prohost Letter #439 The Coronavirus Outbreak - COVID-19 The news announced that the coronavirus (now known …

CRISPR Therapeutics and Sisters

February 13, 2020 0

CRISPR, Intellia and Editas CRISPR Therapeutics (CRSP) announced revenues of Q4 2019 that beat analysts’ expectations. …

Cassava Sciences Has Good News from Alzheimer’s Disease Trial. See Also: Theravance Biopharma

February 12, 2020 0

Cassava Sciences From NEWSWIRE we learned that Cassava Sciences (SAVA), a clinical-stage biotechnology company focusing on Alzheimer’s …

Why Moderna Therapeutics’ Stock Is Down Today

February 11, 2020 0

Moderna Therapeutics’ Stock Price Soared, Then Gave Back Its Gains in Two Consecutive Days To begin …

Exelixis Has Good News for Metastatic Castration-Resistant Prostate Cancer

February 11, 2020 0

Exelixis Announced Results from its CABOMETYX® Combination with Roche's TECENTRIQ® News announced by Exelixis (EXEL) about …

Why Regeneron Stock Is Soaring

February 10, 2020 0

Regeneron Pharmaceuticals Stock is Rallying Regeneron Pharmaceuticals (REGN) stock outperformed last week gaining over $27. The …

A Synopsis of Some Biotech Companies’ Events

February 6, 2020 0

Synopsis The way many bloggers are interpreting the quarterly and yearly biotech companies’ financial results seems …

Could Nektar Product NKTR-214 Become a Blockbuster?

February 4, 2020 0

Nektar Therapeutics NKTR-214: A Blockbuster? Nektar Therapeutics (NKTR) published preclinical data of its immuno-oncology candidate NKTR-214 bempegaldesleukin …

In a Market that Seems to Soar Today Our Eyes Are on These Biotech Firms

February 4, 2020 0

As the Market Seems to Soar Our Eyes Are on the Following Biotech Stocks: Amgen (AMGN): A …

Gilead Stock Is Up 4%. See Also: Who Is Developing Prophylactic Vaccines for Coronavirus and Nektar’s News That Moved the Stock Up Over 8%.

February 3, 2020 0

Gilead Stock Is UP Gilead Sciences' (GILD) provided its antiviral experimental drug remdesivir to physicians for …

Vertex Beats Expectations in 2019 and Promises a Bright Future

January 31, 2020 0

Vertex Beats Expectations in 2019 Vertex (VRTX) reported fourth-quarter and full-year 2019 financial results yesterday. The …

Regenxbio, Moderna Therapeutics and Other Biotech Stocks Posted Gains in a Bad Market Day

January 30, 2020 0

Regenxbio, Moderna and Others Regenxbio (RGNX) announced several poster presentations including interim data from its Phase …

Compugen

January 30, 2020 0

Time to Remember Compugen The time has ripened for our readers and biotech investors to remember …

The European Medicine Agency Validates the Gilead Application for a CAR T Product for Mantle Cell Lymphoma

January 29, 2020 0

The EMA validated the MAA for the Gilead Investigational CAR T Product for MCL Kite, a Gilead …

Why Moderna Stock Is Boosted in Today’s Bad Stock Market Day

January 27, 2020 0

Coronavirus On January 7, 2020, a novel coronavirus (2019-nCoV) was identified in humans in Wuhan City, …

An Evaluation of Biotech Firms Part 3

January 23, 2020 0

A Comprehensive Essay Part 3 In parts 1 and 2 of this comprehensive essay Vertex (VRTX) …

Why Moderna Stock Is Rallying

January 22, 2020 0

In the NEWS: Coronavirus Yesterday the CDC announced the first US case of coronavirus which has …

Forty Seven Continues to Outperform

January 17, 2020 0

Forty Seven On December 21, 2018 Prohost picked Forty Seven (FTSV) at $16.95 adding it to …

Midday January 16, 2020 Outperforming Prohost Picks

January 16, 2020 0

Outperforming Prohost Picks January 16, 2020 at 11:30 am EST MRNA Trading at $21.35 UP $1.01 …

Nektar Is Still a Favorite

January 15, 2020 0

Nektar in the NEWS The FDA's Anesthetic and Analgesic Advisory Committee (AADPAC) and Drug Safety and Risk …

Exclusive Market Insight

& Scientific analysis

Latest Articlesddd

Prohost Letter #439

CRISPR Therapeutics and Sisters

Cassava Sciences Has Good News from Alzheimer’s Disease Trial. See Also: Theravance Biopharma

Why Moderna Therapeutics’ Stock Is Down Today

Exelixis Has Good News for Metastatic Castration-Resistant Prostate Cancer

Why Regeneron Stock Is Soaring

A Synopsis of Some Biotech Companies’ Events

Could Nektar Product NKTR-214 Become a Blockbuster?

In a Market that Seems to Soar Today Our Eyes Are on These Biotech Firms

Gilead Stock Is Up 4%. See Also: Who Is Developing Prophylactic Vaccines for Coronavirus and Nektar’s News That Moved the Stock Up Over 8%.

Vertex Beats Expectations in 2019 and Promises a Bright Future

Regenxbio, Moderna Therapeutics and Other Biotech Stocks Posted Gains in a Bad Market Day

Compugen

The European Medicine Agency Validates the Gilead Application for a CAR T Product for Mantle Cell Lymphoma

Why Moderna Stock Is Boosted in Today’s Bad Stock Market Day

An Evaluation of Biotech Firms Part 3

Why Moderna Stock Is Rallying

Forty Seven Continues to Outperform

Midday January 16, 2020 Outperforming Prohost Picks

Nektar Is Still a Favorite